Ambulero will file an IND for our lead cell therapy product AMB-101 by early 2021.

INVESTORS AND DEVELOPMENT

Initial start-up funding and business support has been provided by Ventac Holding, LLC. Drs. Omaida Velazquez’s and Zhao-Jun Liu's research has been supported by the NIH including funding from the prestigious Vascular Interventions/Innovations and Therapeutic Advances (VITA) program. Dr. Velazquez’ work has also been supported by the The Wallace H. Coulter Center for Translational Research at the University of Miami.

 

The company is also advancing its gene therapy product (AMB-201) to treat critical limb ischemia: a major co-morbidity of diabetes effecting roughly 2 million people in the U.S.

©2020 Ambulero, Inc.

Ambulero, Inc. | 1951 NW 7th Avenue, Ste. 600 | Miami, Florida  33136

  • LinkedIn
  • Twitter